Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
gptkb:33643-46-8
|
| gptkbp:chirality |
(R)-enantiomer
|
| gptkbp:drugClass |
NMDA receptor antagonist
dissociative anesthetic |
| gptkbp:effect |
dissociation
analgesia antidepressant effects (investigational) |
| gptkbp:has_research_use |
neuropharmacology
psychiatric research antidepressant research |
| gptkbp:has_stereochemistry |
(R)-configuration
|
| gptkbp:hasEnantiomer |
gptkb:esketamine
|
| gptkbp:hasMolecularFormula |
C13H16ClNO
|
| https://www.w3.org/2000/01/rdf-schema#label |
arketamine
|
| gptkbp:isomerOf |
gptkb:ketamine
|
| gptkbp:IUPACName |
(R)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
|
| gptkbp:legalStatus |
varies by country
|
| gptkbp:metabolite_of |
gptkb:ketamine
|
| gptkbp:molecularWeight |
237.73 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103837
110061 123590 |
| gptkbp:relatedTo |
gptkb:ketamine
gptkb:esketamine |
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:UNII |
6LR8C1B6OU
|
| gptkbp:bfsParent |
gptkb:ketamine
|
| gptkbp:bfsLayer |
6
|